Light Ai Inc. · NEO:ALGO
Light Ai — Investor Presentation (January 2025)
18 slides from Light Ai's investor presentation, January 2025
Slide 1: Detecting Infectious Diseases Instantly
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Detecting Infectious Diseases Instantly Applying AI to smartphone images to identify disease in seconds – a patented, app-based solution. January 2025 Confidential - Property of Light AI, Inc.
Slide 2: Disclaimer
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Disclaimer This corporate presentation of Light AI Inc. (the “Company”) and the information contained actual results may differ materially from those in the forward-looking statements. Readers are reliance on forward-looking statements due to the inherent uncerta
Slide 3: Light AI is addressing two of the pressing public health issues of our time
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Light AI is addressing two of the pressing public health issues of our time 1. Antimicrobial resistance 2. Strep A Antimicrobial resistance from misuse and overuse of Strep A infects more than 600M people globally every antibiotics is consistently listed as one o
Slide 4: Antibiotic prescriptions for sore throats in the United States
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN In the United States, for every 10 sore throats treated by a physician, there are 6 antibiotic prescriptions written, yet only 2 are actually bacterial infections. Adoption of LightAI’s smartphone diagnostic for Strep A would mean that only the people who need an
Slide 5: Light AI Highlights
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Light AI Highlights Massive infectious footprint + Instant screening results = Hyper scale growth opportunity AI Platform Capital, Time,Partners AI Veterans and Paradigm shift: Light AI has patented an LightAI has raised over $36M (not Healthcare Luminaries AI pl
Slide 6: An Iteratively Improving AI Model
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN An Iteratively Improving AI Model (Multiple Validation Studies) Image Data Base ~60,000 Image Data Base ~50,000 100 Accuracy 97% Image Data Base ~40,000 Accuracy 94% Accuracy 89% 90 96.57% Current Accuracy Image Data Base ~30,000 Accuracy 79% 80 Achieved 100% NPV
Slide 7: Leadership
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Leadership We continue to expand our impact with a team of multidisciplinary experts - across healthcare, technology - steadfast in our belief that technology should serve humanity Officers Advisors Board Peter Whitehead Anthony Schaller Steven Semmelmayer CEO Chai
Slide 8: Problem
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Problem Current Medical Diagnostics System 24-72+ Hours Doctor Visits Lab Test Lab Results Follow-Up Visit Treatment Plan Patient examination with Patient’s specimen sent Additional time required to test Another appointment is Appropriate treatment can referral t
Slide 9: How it works | identifies infection within seconds
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN How it works | identifies infection within seconds Contact HCP Scan Session Initiated Scan Analysis On-Demand Patient and healthcare provider meet over a The patient is prompted to scan their throat. Light AI immediately analyzes the scan data Decision support tha
Slide 10: Strep A | Light AI addresses major unmet needs
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Strep A | Light AI addresses major unmet needs Need for Urgency Costly Infrastructure Low POC Accuracy Strep requires timely test results due to Common tests like a throat swab require A doctor cannot accurately identify Strep the potential health implications an
Slide 11: Go-To-Market paths | LMIC Screening Product
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Go-To-Market paths | LMIC Screening Product Development Objectives: • Develop Android App in addition to existing iOS App ● LMIC* distribution partner is TC4A (Tech Care For All). • Demonstrate functionality for pilot programs • Design and implementation of proto
Slide 12: Go-To-Market paths | wellness (DTC)
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Go-To-Market paths | wellness (DTC) Wellness Product Development Objectives: • Modify existing app for the wellness market ● Wellness (DTC) is expected to be Light AI’s largest market. ● Leverage large distribution ecosystems such as major smartphone. ● No FDA ap
Slide 13: Go-To-Market paths | FDA commercialization plan
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Go-To-Market paths | FDA commercialization plan Clear FDA Pathway Clinical Trial Launch Plan ● De Novo Application ● Single pivotal clinical trial ● Reimbursement Available ● New device category: SaMD (Software as a ● Strong Clinical Dev Partner - Expected to be
Slide 14: Anticipated timeline
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Anticipated timeline *The timing associated with obtaining FDA approval depends heavily on the outcome of the prior clinical studies of the Company and feedback from the FDA, as applicable. The anticipated timeline provided herein is inherently speculative, subje
Slide 15: Light AI granted & allowed patents
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Light AI granted & allowed patents Grant Date: Jun 2022 Grant Date: Mar 2023 Intention to Grant: May 2024 Grant Date: Nov 2024 Patent 1 Patent 2 Patent 3 Patent 4 Image processing of streptococcal Image processing of streptococcal Image processing of streptococca
Slide 16: CAP table
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN CAP table Light AI Inc Capitalization Table Common Shares issued and outstanding 116,230,671 Stock Options 7,113,945 Warrants 24,085,595 Broker Warrants 2,546,860 Fully 149,977,071 Diluted Confidential - Property of Light AI, Inc. 15
Slide 17: Thank you
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN Thank you Peter Whitehead Sheldon Chang Commodity Partners CEO & Founder Light AI sheldon@commoditypartners.ca 604-687-7130 info@light.ai Confidential - Property of Light AI, Inc.
Slide 18: References
CBOE CA: ALGO OTCQB: HHPHF FSE: OHCN References 1 - Ten threats to global health in 2019. World Health Organization. www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. 2 - Torotice D., Ferranna M., Bloom D. (2023). Optimal global spending for group A Streptococcus vaccine research